Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Horwitz

Showing results (71-80 of 208) with videos related to

Pageof 21
Sort By:
Blood|February 15, 2003
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trialBradley C Ekstrand, Jennifer B Lucas, Steven M Horwitz, et al.
Blood|March 22, 2014
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinSteven M Horwitz, Ranjana H Advani, Nancy L Bartlett, et al.
Blood Advances|April 9, 2024
Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and/or NK-cell lymphomaYing Liu, Rohan Sardana, David Nemirovsky, et al.
Cancer Medicine|October 1, 2019
Incidence of benign and malignant peri-implant fluid collections and masses on magnetic resonance imaging in women with silicone implantsElizabeth J Sutton, Brittany Z Dashevsky, Elizabeth J Watson, et al.
British Journal of Haematology|August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin, Carol S Portlock, David J Straus, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2025
Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World CohortRachel E Christensen, Robert Stuver, Stephen Dusza, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 17, 2013
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remissionNeha Mehta, Jocelyn C Maragulia, Allison Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2007
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphomaStephen M Ansell, Steven M Horwitz, Andreas Engert, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL studyFrancine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Haematologica|March 19, 2026
Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targetsRobert Stuver, Haiming Tang, Ahmet Dogan, et al.
Pageof 21

Showing results (71-80 of 208) with videos related to

Sort By:
Pageof 21
Blood|February 15, 2003
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trialBradley C Ekstrand, Jennifer B Lucas, Steven M Horwitz, et al.
Blood|March 22, 2014
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinSteven M Horwitz, Ranjana H Advani, Nancy L Bartlett, et al.
Blood Advances|April 9, 2024
Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and/or NK-cell lymphomaYing Liu, Rohan Sardana, David Nemirovsky, et al.
Cancer Medicine|October 1, 2019
Incidence of benign and malignant peri-implant fluid collections and masses on magnetic resonance imaging in women with silicone implantsElizabeth J Sutton, Brittany Z Dashevsky, Elizabeth J Watson, et al.
British Journal of Haematology|August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin, Carol S Portlock, David J Straus, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2025
Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World CohortRachel E Christensen, Robert Stuver, Stephen Dusza, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 17, 2013
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remissionNeha Mehta, Jocelyn C Maragulia, Allison Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2007
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphomaStephen M Ansell, Steven M Horwitz, Andreas Engert, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL studyFrancine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Haematologica|March 19, 2026
Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targetsRobert Stuver, Haiming Tang, Ahmet Dogan, et al.
Pageof 21